Article Sidebar

Submitted
16 September 2020
Accepted
8 November 2021
Published
7 December 2021
Download
PDF
Statistic
Read Counter : 500 Download : 311

Main Article Content

Abstract

Highlight:

  1. The correlation of IL-17 to disease activity by The Ankylosing Spondylitis Disease Activity Score C-Reactive Protein (ASDAS-CRP) was identified.
  2.  IL-17 level is strongly correlated to disease activity in SpA patients.
 

Abstract:

IL-17 is a new cytokine involved in the pathogenesis of Spondyloarthritis (SpA). Recent studies show that IL-17 level correlates to disease activity, and it is used as a basis in treating SpA patients who do not respond to anti-TNF-α. This study identified the correlation of IL-17 to disease activity measured by The Ankylosing Spondylitis Disease Activity Score C-Reactive Protein (ASDAS-CRP). This study was a cross-sectional study involving SpA patients according to the 2009 ASAS criteria in Dr. Soetomo General Academic Hospital, Surabaya. Disease activity and IL-17 level were analyzed using Spearman correlation test to see the strength of correlation. Forty SpA patients showed mean age of 53.58 ± 9.28 years with a body mass index of 24.36 ± 3.23 kg/m2, ESR of 39.50 ± 18.76 mm/hour, clinically obtained Schober Test of 13.11 ± 1.22 cm, chest extension test of 1.45 ± 0.77 cm, and tragus-to-wall test 13.53 ± 1.99 cm. The median CRP and IL-17 were 0.3 (0.10-5.70) mg/dL and 9.30 (7.70-13.60) pg/dL, respectively. Based on the ASDAS-CRP system, the patients showed disease activities that fall into the category was high (62.5%), moderate (35%), and inactivity (2.5%). IL-17 level is strongly correlated to disease activity in SpA patients (p=0.000, r = 0.711).

Keywords

IL-17 spondyloarthritis health risks disease

Article Details

License

Copyright (c) 2021 Yuliasih Yuliasih, Yusdeny Lanasakti

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Yuliasih, & Lanasakti, Y. (2021). IL-17 and Disease Activity in Spondyloarthitis. Folia Medica Indonesiana, 57(4), 289–297. https://doi.org/10.20473/fmi.v57i4.22073
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Appel H, Maier R, Wu P, et al (2011). Analysis of Il-17+cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the th17-mediated adaptive immune response. Arthritis Research & Therapy 13, 1-9.
  2. Arican O, Aral M, Sasmaz S, et al (2005). Serum levels of Tnf-alpha, Ifn-gamma, Il-6, Il-8, Il-12, Il-17, and Il-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005, 273-279.
  3. Ballantyne FC, Fleck A, Dick WC (1971). Albumin Metabolism in rheumatoid arthritis. Annals of The Rheumatic Diseases 30, 265-270.
  4. Baraliakos X, Kiltz U, Heldmann F, et al (2014). Thu0108 different performance of the major disease activity measures asdas and basdai in patients with axial spondyloarthritis treated with non-steroidal anti-inflammatory agents (Nsaids) - Results from a prospective study. Annals of The Rheumatic Diseases 73, 214-215.
  5. Braun T, Zwerina J (2011). Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Research & Therapy 13, 1-11.
  6. Chabaud M, Garnero P, Dayer J-M, et al (2000). Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 12, 1092-1099.
  7. Chen W-S, Chang Y-S, Lin K-C, et al (2012). Association of serum interleukin-17 and interleukin-23 levels with disease activity in chinese patients with ankylosing spondylitis. Journal of The Chinese Medical Association 75, 303-308.
  8. Chowdhury S, Dijkhuis A, Steiert S, et al (2013). Il-17 attenuates degradation of are-mrnas by changing the cooperation between au-binding proteins and microrna16. Plos Genetics 9, 1-13.
  9. Ciprandi G, Fenoglio D, De Amici M, et al (2008). Serum Il-17 levels in patients with allergic rhinitis. Journal of Allergy And Clinical Immunology 122, 650-651.
  10. Colbert RA, Delay ML, Layh-Schmitt G, et al (2009). Hla-B27 misfolding and spondyloarthropathies. Prion 3, 15-26.
  11. Dincer U, Cakar E, Kiralp MZ, et al (2008). Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol 27, 457-462.
  12. Dougados M, Maetzel A, Mijiyawa M, et al (1992). Evaluation Of sulphasalazine in the treatment of spondyloarthropathies. Annals of The Rheumatic Diseases 51, 955-958.
  13. Dudler J, Renggli-Zulliger N, Busso N, et al (2000). Effect of interleukin 17 on proteoglycan degradation in murine knee joints. Annals of The Rheumatic Diseases 59, 529-532.
  14. Ehrenfeld M (2012). Spondyloarthropathies. Best Practice & amp; Research. Clinical Rheumatology 26, 135-145.
  15. Gallinaro A, Ventura C, Sampaio-Barros P, et al (2010). Spondyloarthritis: Analysis of a Brazilian series compared with a large ibero-american registry (respondia group). Revista Brasileira De Reumatologia 50, 581-589.
  16. Honorati MC, Bovara M, Cattini L, et al (2002). Contribution Of interleukin 17 to human cartilage degradation and synovial inflammation in osteoarthritis. Osteoarthritis and Cartilage 10, 799-807.
  17. Hot A, Miossec P (2011). Effects of interleukin (Il)-17a and Il-17f in human rheumatoid arthritis synoviocytes. Annals of The Rheumatic Diseases 70, 727-732.
  18. Hussein MR, Fathi NA, El-Din AME, et al (2008). Alterations of the Cd4+, Cd8+ T cell subsets, interleukins-1β, Il-10, Il-17, tumor necrosis factor-Α and soluble intercellular adhesion molecule-1 in rheumatoid arthritis and osteoarthritis: preliminary observations. Pathology & Oncology Research 14, 321-328.
  19. Jeffrey AO, Bambang S, IdaArthur O, et al (2010). Correlation of interleukin-17 with disease activity and hand joint damage in patients with rheumatoid arthritis. Indonesian Journal of Rheumatology 2, 26-30.
  20. Julija Z, Inita B, Liene N-Z, et al (2013). A10.18 lack of association of serum interleukin-17 and interleukin-23 levels with disease activity in patients with ankylosing spondylitis in Latvia. Annals of The Rheumatic Diseases 72, A78-A78.
  21. Kay J, Morgacheva O, Messing SP, et al (2014). Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Research & Therapy 16, R40-R40.
  22. Koenders MI, Kolls JK, Oppers-Walgreen B, et al (2005). Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum 52, 3239-3247.
  23. Machado P, Landewé R, Lie E, et al (2011). Ankylosing spondylitis disease activity score (Asdas): Defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70, 47-53.
  24. Madej M, Nowak B, Åšwierkot J, et al (2015). Cytokine profiles in axial spondyloarthritis. Reumatologia 53, 9-13.
  25. Mcguckin MA, Eri RD, Das I, et al (2010). Er stress and the unfolded protein response in intestinal inflammation. American Journal of Physiology-Gastrointestinal and Liver Physiology 298, G820-G832.
  26. Miossec P, Kolls JK (2012). Targeting Il-17 and Th17 cells in chronic inflammation. Nature Reviews Drug Discovery 11, 763-776.
  27. Moz S, Aita A, Basso D, et al (2017). Spondyloarthritis: Matrix metalloproteinases as biomarkers of pathogenesis and response to tumor necrosis factor (Tnf) inhibitors. International Journal of Molecular Sciences 18, 1-14.
  28. Onishi RM, Gaffen SL (2010). Interleukin-17 and its target genes: Mechanisms of interleukin-17 Function in disease. Immunology 129, 311-321.
  29. Park YE, Woo YJ, Park SH, et al (2011). Il-17 increases cadherin-11 expression in a model of autoimmune experimental arthritis and in rheumatoid arthritis. Immunol Lett 140, 97-103.
  30. Petersen AMW, Pedersen BK (2005). The Anti-inflammatory effect of exercise. Journal of Applied Physiology 98, 1154-1162.
  31. Pinto LG, Cunha TM, Vieira SM, et al (2010). Il-17 mediates articular hypernociception in antigen-induced arthritis in mice. Pain 148, 247-256.
  32. Richter F, Natura G, Ebbinghaus M, et al (2012). Interleukin-17 sensitizes joint nociceptors to mechanical stimuli and contributes to arthritic pain through neuronal interleukin-17 receptors in rodents. Arthritis & Rheumatism 64, 4125-4134.
  33. Ruddy MJ, Shen F, Smith JB, et al (2004). Interleukin-17 regulates expression of the Cxc chemokine Lix/Cxcl5 in osteoblasts: Implications for inflammation and neutrophil recruitment. Journal of Leukocyte Biology 76, 135-144.
  34. Rudwaleit M (2010). New approaches to diagnosis and classification of axial and peripheral spondyloarthritis. Current Opinion in Rheumatology 22, 375-380.
  35. Siloşi I, Boldeanu MV, Cojocaru M, et al (2016). The relationship of cytokines Il-13 and Il-17 with autoantibodies profile in early rheumatoid arthritis. Journal of Immunology Research 2016, 1-10.
  37. Singh R, Aggarwal A, Misra R (2007). Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. The Journal of Rheumatology 34, 2285-2290.
  38. Taams LS, Steel KJA, Srenathan U, et al (2018). Il-17 in the immunopathogenesis of spondyloarthritis. Nature Reviews Rheumatology,14, 453-466.
  39. Tayel MY, Soliman E, El Baz WF, et al (2012). Registry of the clinical characteristics of spondyloarthritis in a cohort of the Egyptian population. Rheumatology International 32, 2837-2842.
  40. Wang X, Lin Z, Wei Q, et al (2009). Expression Of Il-23 and Il-17 and effect of Il-23 on Il-17 production in ankylosing spondylitis. Rheumatology International 29, 1343-1347.
  41. Wendling D, Cedoz J-P, Racadot E, et al (2007). Serum Il-17, Bmp-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 74, 304-305.
  42. Woloshin S, Schwartz LM (2005). Distribution of C-reactive protein values in the United States. New England Journal of Medicine 352, 1611-1613.
  43. Yago T, Nanke Y, Ichikawa N, et al (2009). Il-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-Tnf-Α antibody: A novel mechanism of osteoclastogenesis by Il-17. Journal of Cellular Biochemistry 108, 947-955.
  44. Yang C, Gu J, Rihl M, et al (2004). Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis and Rheumatism 51, 691-699.
  45. Yildirim K, Melikoglu M, Gureser G, et al (2004). Association between acute phase reactant levels and disease activity score (Das28) In patients with rheumatoid arthritis. Annals of Clinical and Laboratory Science 4, 423-426.
  46. Zhang S, Li Y, Deng X, et al (2011). Similarities and differences between spondyloarthritis in Asia and other parts of the world. Current Opinion in Rheumatology 23, 334-338.